Skip to main
ANRO
ANRO logo

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience Inc. has made significant strides in its clinical-stage biopharmaceutical development, particularly with ALTO-207 (CTC-501), which has shown improvements in tolerability compared to pramipexole, allowing for higher doses and a fast titration regimen that could enhance treatment benefits for depressive symptoms. Additionally, the new transdermal formulation of ALTO-101 has exhibited an improved safety profile and favorable pharmacokinetics, which are encouraging indicators for its ongoing Phase 2 study in CIAS patients. These advancements position Alto Neuroscience favorably within its target market, reflecting a strong potential for positive clinical outcomes and market acceptance of its personalized treatment approaches.

Bears say

Alto Neuroscience Inc has faced significant pressure on its stock since its IPO in 2024, primarily due to the failure of its lead asset, ALTO-100, in a Phase 2b study for major depressive disorder. Additionally, the ongoing Phase 2b study in bipolar depression is viewed as a high-risk program with a low probability of success, further dampening investor sentiment. Compounding these challenges, negative data related to ALTO-300 has raised concerns about the company’s overall pipeline and future growth potential.

ANRO has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Buy based on their latest research and market trends.

According to 6 analysts, ANRO has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.